Restricted accessResearch articleFirst published online 2024-12
Impact of Missed and Late Meal Boluses on Glycemic Outcomes in Automated Insulin Delivery-Treated Children and Adolescents with Type 1 Diabetes: A Two-Center,Population-Based Cohort Study
To evaluate the impact of missed or late meal boluses (MLBs) on glycemic outcomes in children and adolescents with type 1 diabetes using automated insulin delivery (AID) systems.
Research Design and Methods:
AID-treated (Tandem Control-IQ or Medtronic MiniMed 780G) children and adolescents (aged 6–21 years) from Stanford Medical Center and Steno Diabetes Center Copenhagen with ≥10 days of data were included in this two-center, binational, population-based, retrospective, 1-month cohort study. The primary outcome was the association between the number of algorithm-detected MLBs and time in target glucose range (TIR; 70–180 mg/dL).
Results:
The study included 189 children and adolescents (48% females with a mean ± standard deviation age of 13 ± 4 years). Overall, the mean number of MLBs per day in the cohort was 2.2 ± 0.9. For each additional MLB per day, TIR decreased by 9.7% points (95% confidence interval [CI] 11.3; 8.1), and compared with the quartile with fewest MLBs (Q1), the quartile with most (Q4) had 22.9% less TIR (95% CI: 27.2; 18.6). The age-, sex-, and treatment modality-adjusted probability of achieving a TIR of >70% in Q4 was 1.4% compared with 74.8% in Q1 (P < 0.001).
Conclusions:
MLBs significantly impacted glycemic outcomes in AID-treated children and adolescents. The results emphasize the importance of maintaining a focus on bolus behavior to achieve a higher TIR and support the need for further research in technological or behavioral support tools to handle MLBs.
Get full access to this article
View all access options for this article.
References
1.
MaurasN, BuckinghamB, WhiteNH, et al.Impact of type 1 diabetes in the developing brain in children: A longitudinal study. Diabetes Care, 2021; 44(4):983–992.
2.
Stern-ZimmerM, Calderon-MargalitR, SkoreckiK, et al.Childhood risk factors for adulthood chronic kidney disease. Pediatr Nephrol, 2021; 36(6):1387–1396.
3.
SamuelssonJ, SamuelssonU, HanbergerL, et al.Poor metabolic control in childhood strongly correlates to diabetes-related premature death in persons. Pediatr Diabetes, 2020; 21(3):479–485.
4.
SaiyedM, HasnaniD, AlonsoGT, et al.Worldwide differences in childhood type 1 diabetes: The SWEET experience. Pediatr Diabetes, 2021; 22(2):207–214.
5.
RobinsonS, NewsonRS, LiaoB, et al.Missed and mistimed insulin doses in people with diabetes: A systematic literature review. Diabetes Technol Ther, 2021; 23(12):844–856.
6.
CollynsOJ, MeierRA, BettsZL, et al.Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care, 2021; 44(4):969–975.
7.
ElsayedNA, AleppoG, ArodaVR, et al.Children and adolescents: Standards of care in diabetes-2023. Diabetes Care, 2023; 46(Suppl 1):S230–S253.
8.
PhillipM, NimriR, BergenstalRM, et al.Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev, 2023; 44(2):254–280.
9.
EbekozienO, NoorN, DimeglioL, et al.1456-P: 2022 state of type 1 diabetes in the U.S.—real world T1D exchange multicenter data from over 60,000 People. Diabetes, 2023; 72(Supplement_1).
10.
BretonMD, KanapkaLG, BeckRW, et al.A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383(9):836–845.
11.
CarlsonAL, SherrJL, ShulmanDI, et al.Safety and glycemic outcomes during the MiniMedTM advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24(3):178–189.
12.
BattelinoT, AlexanderCM, AmielSA, et al.Continuous glucose monitoring and metrics for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol, 2023; 11(1):42–57.
13.
ArrietaA, BattelinoT, ScaramuzzaAE, et al.Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab, 2022; 24(7):1370–1379.
14.
NgSM, WrightNP, YardleyD, et al.Real world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus-A national health service pilot initiative in England. Diabet Med, 2023; 40(2):e15015.
15.
BretonMD, KovatchevBP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23(9):601–608.
16.
DovcK, LanzingerS, Cardona-HernandezR, et al.Association of achieving time in range clinical targets with treatment modality among youths with type 1 diabetes. JAMA Netw Open, 2023; 6(2):e230077.
17.
CampbellMS, SchatzDA, ChenV, et al.A contrast between children and adolescents with excellent and poor control: The T1D Exchange clinic registry experience. Pediatr Diabetes, 2014; 15(2):110–117.
18.
BurdickJ, ChaseHP, SloverRH, et al.Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics, 2004; 113(3 Pt 1):e221–e224.
19.
DatyeKA, BoyleCT, SimmonsJ, et al.Timing of meal insulin and its relation to adherence to therapy in type 1 diabetes. J Diabetes Sci Technol, 2018; 12(2):349–355.
20.
OlinderAL, KernellA, SmideB. Missed bolus doses: Devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes, 2009; 10(2):142–148.
21.
ToschiE, SlyneC, GreenbergJM, et al.Examining the relationship between pre- and postprandial glucose levels and insulin bolus timing using Bluetooth-enabled insulin pen cap technology and continuous glucose monitoring. Diabetes Technol Ther, 2020; 22(1):19–24.
22.
AdolfssonP, HartvigNV, KaasA, et al.Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther, 2020; 22(10):709–718.
23.
EdwardsS, HeX, WangW, et al.Use of connected pen as a diagnostic tool to evaluate missed bolus dosing behavior in people with type 1 and type 2 diabetes. Diabetes Technol Ther, 2022; 24(1):61–66.
24.
NorlanderLM, AndersonS, LevyCJ, et al.Late and missed meal boluses with multiple daily insulin injections. Diabetes, 2018; 67(Supplement_1).
25.
MacLeodJ, ImGH, SmithM, et al.Shining the spotlight on multiple daily insulin therapy: Real-world evidence of the InPen smart insulin pen. Diabetes Technol Ther, 2024; 26(1):33–39.
26.
KovatchevBP, SinghH, MuellerL, et al.Biobehavioral changes following transition to automated insulin delivery: A large real-life database analysis. Diabetes Care, 2022; 45(11):2636–2643.
27.
TorneseG, CarlettiC, GiangrecoM, et al.Carbohydrate tolerance threshold for unannounced snacks in children and adolescents with type 1 diabetes using an advanced hybrid closed-loop system. Diabetes Care, 2022; 45(6):1486–1488.
28.
MarksBE, MeighanS, ZehraA, et al.Real-world glycemic outcomes with early Omnipod 5 use in youth with type 1 diabetes. Diabetes Technol Ther, 2023; 25(11):782–789.
29.
SchoelwerMJ, KanapkaLG, WadwaRP, et al.Predictors of time-in-range (70–180 mg/dL) achieved using a closed-loop control system. Diabetes Technol Ther, 2021; 23(7):475–481.
30.
CoutantR, BismuthE, BonnemaisonE, et al.Hybrid closed loop overcomes the impact of missed or suboptimal meal boluses on glucose control in children with type 1 diabetes compared to sensor-augmented pump therapy. Diabetes Technol Ther, 2023; 25(6):395–403.
31.
ShalitR, MinskyN, Laron-HirshM, et al.Unannounced meal challenges using an advanced hybrid closed-loop system. Diabetes Technol Ther, 2023; 25(9):579–588.
32.
AkturkHK, Snell-BergeonJ, ShahVN. Efficacy and safety of Tandem Control IQ without user-initiated boluses in adults with uncontrolled type 1 diabetes. Diabetes Technol Ther, 2022; 24(10):779–783.
33.
ElleriD, MaltoniG, AllenJM, et al.Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: A randomized clinical trial. Diabetes Obes Metab, 2014; 16(11):1174–1178.
34.
CherñavvskyDR, DeboerMD, Keith-HynesP, et al.Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr Diabetes, 2016; 17(1):28–35.
35.
MesserLH, MuellerL, D’SouzaEW, et al.61-OR: Mobile bolus feature improves bolus behavior in Control-IQ users who bolus <3 times/day. Diabetes, 2023; 72(Supplement_1).
36.
RoyA, GrossmanB, EngelT, et al.OP029: An automated insulin delivery (AID) system with automatic meal bolus based on a hand-gesturing algorithm. Diabetes Technology & Therapeutics, 2023; 25(S2):A-1–A-269.
DassauE, BequetteBW, BuckinghamBA, et al.Detection of a meal using continuous glucose monitoring: Implications for an artificial beta-cell. Diabetes Care, 2008; 31(2):295–300.
39.
PalisaitisE, El FathiA, von OettingenJE, et al.A meal detection algorithm for the artificial pancreas: A randomized controlled clinical trial in adolescents with type 1 diabetes. Diabetes Care, 2021; 44(2):604–606.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
